Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 21;10(1):67–74. doi: 10.1002/psp4.12578

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Estimated survival with 95% confidence intervals for two simulated patients with matching baseline SLD and NLR values: good vs. poor prognosis represented by biomarker changes over 3 months after start of treatment. (a) SLD is either increased or decreased, and NLR remains constant. (b) NLR is either increased or decreased, and SLD remains constant, (c) Both SLD and NLR are either increased or decreased. NLR, neutrophil‐to‐lymphocyte ratio; SLD, sum of the longest diameters.